A Novel Yolk-Shell Fe3O4@ Mesoporous Carbon Nanoparticle as an Effective Tumor-Targeting Nanocarrier for Improvement of Chemotherapy and Photothermal Therapy

Int J Mol Sci. 2022 Jan 30;23(3):1623. doi: 10.3390/ijms23031623.

Abstract

Owing to their good stability and high photothermal conversion efficiency, the development of carbon-based nanoparticles has been intensively investigated, while the limitation of unsatisfactory cellular internalization impedes their further clinical application. Herein, we report a novel strategy for fabrication of Fe3O4 yolk-shell mesoporous carbon nanocarriers (Fe3O4@hmC) with monodispersity and uniform size, which presented significantly higher cell membrane adsorption and cellular uptake properties in comparison with common solid silica-supported mesoporous carbon nanoparticles with core-shell structure. Moreover, the MRI performance of this novel Fe-based nanoparticle could facilitate precise tumor diagnosis. More importantly, after DOX loading (Fe3O4@hmC-DOX), owing to synergistic effect of chemo-phototherapy, this therapeutic agent exhibited predominant tumor cell ablation capability under 808 nm NIR laser irradiation, both in vitro and in vivo. Our work has laid a solid foundation for therapeutics with hollowed carbon shell for solid tumor diagnosis and therapy in clinical trials.

Keywords: Fe3O4; MRI; chemotherapy; mesoporous carbon; photothermal therapy; yolk–shell.

MeSH terms

  • Animals
  • Breast Neoplasms / diagnostic imaging
  • Breast Neoplasms / therapy*
  • Carbon / chemistry*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • Combined Modality Therapy
  • Doxorubicin / administration & dosage*
  • Doxorubicin / chemistry
  • Female
  • Magnetic Iron Oxide Nanoparticles / chemistry*
  • Mice
  • Nanostructures
  • Particle Size
  • Photothermal Therapy
  • Treatment Outcome
  • Xenograft Model Antitumor Assays

Substances

  • Carbon
  • Doxorubicin